March 8, 2010

Pfizer Cholesterol Flops Cleared Path for Resverlogix

By Kelley Luckstein

Resverlogix Corp., without a marketed product, may accomplish what Pfizer Inc., the world’s biggest drugmaker, couldn’t: Creating a new medicine that fights heart disease by raising so-called good cholesterol…


Resverlogix is banking that artificially raising HDL will have the same effect. Only one treatment now commercially available is marketed to increase good cholesterol. Niacin, a B vitamin, elevates HDL “but it’s not clear whether it lowers cardiac events,” according to Stephen Kopecky, a cardiologist at the Mayo Clinic in Rochester, Minnesota.


BusinessWeek, by Ellen Gibson, 3/5/2010

Tags: cardiac events, Cardiology, cholesterol, Dr. Stephen Kopecky, Resverlogix

Please sign in or register to post a reply.
Contact Us · Privacy Policy